Pulmonary vascular disease & thromboembolism
Indefinite Anticoagulant Therapy for First Unprovoked Venous Thromboembolism : A Cost-Effectiveness Study
Study context
- Population
- Patients with a first unprovoked venous thromboembolism (VTE) who completed 3 to 6 months of initial anticoagulant treatmenthypothetical cohort aged 55 years
- Participants
- 1,000 patients
- Comparison
- Indefinite anticoagulation with DOACs vs discontinuing anticoagulation after initial treatment
- Outcome
- Recurrent VTE events, major bleeding events, costs (2022 Canadian dollars) and QALYs
- Follow-up
- Lifetime
Methodological detailslifetime time horizon, Canadian health care public payer perspective, Model assumed risks for recurrent VTE and major bleeding measured in trials at 1 year remained constant during extended anticoagulation
- Lifetime time horizon
- Canadian health care public payer perspective
- Model assumed risks for recurrent VTE and major bleeding measured in trials at 1 year remained constant during extended anticoagulation
Main finding
As reported in the abstract
Base-case analysis
Difference
16 014 CAD $ per person
cost
Difference
−0.075 QALYs per person
did not increase quality-adjusted life-years (QALYs)
- Recurrent VTE events prevented per 1000 patients
- 368
- Fatal pulmonary emboli prevented (included in recurrent VTE)
- 14
Further findings
Sensitivity analysis
- Results most sensitive to case-fatality rate of major bleeding and annual risk for major bleeding during extended anticoagulation
Safety
Major bleeding (additional events per 1000 patients) · Lifetime
- Additional major bleeding events
- 114
- Intracranial hemorrhages
- 30
- Deaths from bleeding
- 11
Original publication
Indefinite Anticoagulant Therapy for First Unprovoked Venous Thromboembolism : A Cost-Effectiveness Study. Ann Intern Med. Published 27 June 2023. doi:10.
Composed by AI from the published abstract and checked against it. How Briefs are made →